David W Dempster
Overview
Explore the profile of David W Dempster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
5760
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheller E, McDonald M, Andersen T, Sumner D, Noda M, Erben R, et al.
JBMR Plus
. 2024 Jun;
8(7):ziae070.
PMID: 38868596
The International Society of Bone Morphometry (ISBM) is dedicated to advancing research, education, and clinical practice for osteoporosis and other bone disorders by developing and improving tools for the quantitative...
2.
Thio Q, van Wulfften Palthe O, Bramer J, DeLaney T, Bredella M, Dempster D, et al.
Calcif Tissue Int
. 2023 Nov;
113(6):640-650.
PMID: 37910222
Despite the risk of complications, high dose radiation therapy is increasingly utilized in the management of selected bone malignancies. In this study, we investigate the impact of moderate to high...
3.
Lewiecki E, Bilezikian J, Binkley N, Bouxsein M, Bukata S, Dempster D, et al.
J Clin Densitom
. 2022 Oct;
25(4):649-667.
PMID: 36280582
The 22 Annual Santa Fe Bone Symposium (SFBS) was a hybrid meeting held August 5-6, 2022, with in-person and virtual attendees. Altogether, over 400 individuals registered, a majority of whom...
4.
Paschalis E, Gamsjaeger S, Klaushofer K, Shane E, Cohen A, Stepan J, et al.
Bone
. 2022 Jul;
162:116478.
PMID: 35779845
Postmenopausal osteoporosis (PMOP) therapies are frequently evaluated by bone mineral density (BMD) gains against patients receiving placebo (calcium and vitamin D supplementation, a mild bone turnover-suppressing intervention), which is not...
5.
Farlay D, Rizzo S, Dempster D, Huang S, Chines A, Brown J, et al.
J Bone Miner Res
. 2022 Mar;
37(5):856-864.
PMID: 35249242
In postmenopausal women with osteoporosis, denosumab (DMAb) therapy through 10 years resulted in significantly higher degree of mineralization of bone, with a subsequent increase from years 2-3 to year 5...
6.
Rooney A, Dempster D, Nieves J, Zhou H, Bostrom M, Cosman F
Bone
. 2022 Jan;
157:116342.
PMID: 35092891
Purpose: We have previously shown that a brief course of teriparatide (TPTD) stimulates bone formation in the cancellous and endocortical envelopes of the human femoral neck, and the regions of...
7.
Cohen A, Hostyk J, Baugh E, Buchovecky C, Aggarwal V, Recker R, et al.
Bone
. 2021 Nov;
154:116253.
PMID: 34743040
Osteoporosis in premenopausal women with intact gonadal function and no known secondary cause of bone loss is termed idiopathic osteoporosis (IOP). Women with IOP diagnosed in adulthood have profound bone...
8.
Tourolle D, Dempster D, Ledoux C, Boaretti D, Aguilera M, Saleem N, et al.
JBMR Plus
. 2021 Jun;
5(6):e10494.
PMID: 34189383
Postmenopausal osteoporosis is a disease manifesting in degradation of bone mass and microarchitecture, leading to weakening and increased risk of fracture. Clinical trials are an essential tool for evaluating new...
9.
Papapoulos S, Bone H, Cosman F, Dempster D, McClung M, Nakamura T, et al.
J Bone Miner Res
. 2021 Mar;
36(7):1225-1234.
PMID: 33724542
We prospectively assessed, with predefined criteria, the location and rates of all femur fractures (hip, subtrochanteric/femoral shaft [ST/FS], including atypical [AFF] and distal fractures) in women at increased fracture risk...
10.
Cosman F, Dempster D
Curr Osteoporos Rep
. 2021 Feb;
19(2):189-205.
PMID: 33635520
Purpose Of Review: There are now three anabolic agents available for the treatment of postmenopausal women at high risk for fracture. The purpose of this review is to supply a...